Dr. Reddy's Laboratories Limited

BSE:500124 Stock Report

Market Cap: ₹994.0b

Dr. Reddy's Laboratories Valuation

Is 500124 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500124 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500124 (₹1193.35) is trading above our estimate of fair value (₹974.03)

Significantly Below Fair Value: 500124 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500124?

Key metric: As 500124 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 500124. This is calculated by dividing 500124's market cap by their current earnings.
What is 500124's PE Ratio?
PE Ratio18.6x
Earnings₹53.33b
Market Cap₹994.02b

Price to Earnings Ratio vs Peers

How does 500124's PE Ratio compare to its peers?

The above table shows the PE ratio for 500124 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.6x
500420 Torrent Pharmaceuticals
58.3x22.7%₹1.1t
ZYDUSLIFE Zydus Lifesciences
22.2x0.6%₹950.6b
500257 Lupin
35.3x16.5%₹928.3b
CIPLA Cipla
26.4x7.3%₹1.2t
500124 Dr. Reddy's Laboratories
18.6x-1.0%₹994.0b

Price-To-Earnings vs Peers: 500124 is good value based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (35.6x).

Price to Earnings Ratio vs Industry

How does 500124's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2xn/aUS$13.15m
No more companies available in this PE range
500124 18.6xIndustry Avg. 32.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 500124 is good value based on its Price-To-Earnings Ratio (18.6x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 500124's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500124 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.6x
Fair PE Ratio34.9x

Price-To-Earnings vs Fair Ratio: 500124 is good value based on its Price-To-Earnings Ratio (18.6x) compared to the estimated Fair Price-To-Earnings Ratio (34.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 500124 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,193.35
₹1,336.87
+12.0%
12.0%₹1,655.00₹969.00n/a39
Nov ’25₹1,258.55
₹1,322.95
+5.1%
12.3%₹1,713.00₹941.00n/a39
Oct ’25₹1,349.39
₹1,327.00
-1.7%
11.5%₹1,602.00₹941.00n/a38
Sep ’25₹1,405.84
₹1,324.06
-5.8%
11.3%₹1,602.00₹941.00n/a37
Aug ’25₹1,378.86
₹1,313.21
-4.8%
11.4%₹1,602.00₹941.00n/a36
Jul ’25₹1,270.30
₹1,232.29
-3.0%
11.7%₹1,500.00₹849.00n/a36
Jun ’25₹1,157.51
₹1,218.68
+5.3%
11.4%₹1,500.00₹849.00n/a37
May ’25₹1,241.02
₹1,199.06
-3.4%
10.8%₹1,357.00₹783.00n/a36
Apr ’25₹1,250.17
₹1,195.52
-4.4%
11.3%₹1,517.40₹783.00n/a36
Mar ’25₹1,239.48
₹1,193.77
-3.7%
11.2%₹1,517.40₹783.00n/a37
Feb ’25₹1,197.97
₹1,191.63
-0.5%
11.1%₹1,517.40₹783.00n/a37
Jan ’25₹1,163.81
₹1,134.35
-2.5%
10.7%₹1,310.00₹754.60n/a37
Dec ’24₹1,149.48
₹1,132.06
-1.5%
10.7%₹1,310.00₹754.60n/a38
Nov ’24₹1,069.52
₹1,137.22
+6.3%
10.9%₹1,312.00₹754.60₹1,258.5538
Oct ’24₹1,117.35
₹1,109.61
-0.7%
11.7%₹1,312.00₹758.80₹1,349.3938
Sep ’24₹1,115.64
₹1,103.21
-1.1%
12.2%₹1,312.00₹758.80₹1,405.8439
Aug ’24₹1,132.83
₹1,099.05
-3.0%
12.0%₹1,312.00₹758.80₹1,378.8639
Jul ’24₹1,031.20
₹994.76
-3.5%
11.5%₹1,200.00₹710.00₹1,270.3036
Jun ’24₹910.24
₹993.51
+9.1%
11.3%₹1,200.00₹710.00₹1,157.5138
May ’24₹985.30
₹993.14
+0.8%
9.8%₹1,178.00₹710.00₹1,241.0238
Apr ’24₹924.30
₹982.24
+6.3%
9.5%₹1,178.00₹710.00₹1,250.1738
Mar ’24₹869.39
₹978.80
+12.6%
9.4%₹1,178.00₹710.00₹1,239.4839
Feb ’24₹870.10
₹976.71
+12.3%
9.6%₹1,178.00₹710.00₹1,197.9739
Jan ’24₹846.88
₹1,000.25
+18.1%
9.3%₹1,192.00₹720.00₹1,163.8138
Dec ’23₹894.45
₹1,000.25
+11.8%
9.3%₹1,192.00₹720.00₹1,149.4838
Nov ’23₹907.96
₹1,000.52
+10.2%
9.2%₹1,192.00₹720.00₹1,069.5238

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹21.8b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹348.90

7D

-11.3%

1Y

-16.9%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹923.05

7D

-4.4%

1Y

17.0%

Bal Pharma

₹1.9b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹126.55

7D

5.0%

1Y

14.2%